On 27 March 2019, Phosphagenics announced that Dr. Ross Murdoch will step down from his role as Chief Executive Officer, and becoming a Non-Executive Director effective April 1, 2019. The Board had agreed to the early release from his six-month notice period, in exchange for Dr. Murdoch releasing Phosphagenics from paying any outstanding contractual entitlements. Dr. Greg Collier will assume the role of Executive Chairman from Non-Executive Chairman, effective April 1, 2019 and will be closely supported by Dr. Paul Gavin (Chief Scientific Officer) and Dr. Roksan Libinaki (GM Animal Health & Production) who will make up the Executive Management team.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.003 AUD | 0.00% | 0.00% | -14.29% |
16/05 | Avecho Biotechnology Doses First Patient in Phase III Anti-Insomnia Drug Trial | MT |
25/03 | Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial | MT |
1st Jan change | Capi. | |
---|---|---|
-14.29% | 6.26M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- AVE Stock
- News Avecho Biotechnology Limited
- Phosphagenics Limited Announces Management Changes, Effective from April 1, 2019